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ABSTRACT
Background and Aims:
Dysglycemia, consisting of diabetes mellitus (DM), impaired glucose tolerance 
(IGT) and impaired fasting glucose (IFG), is a common comorbid of COPD. High 
prevalence of dysglycemia in COPD is well-recognized, however data comparing 
COPD exacerbation with incidence of dysglycemia is scarce. Thus, this study aimed 
to determine whether COPD exacerbation is a risk factor for dysglycemia.
Materials and Methods:
This is a cross-sectional study involving patients with established COPD aged 30 
years and above (n=186) attending respiratory specialist clinics in UiTM campuses. 
Those on long-term corticosteroid therapy, active malignancy or in peripartum 
periods were excluded. Patients were divided into those with or without hospital 
admission for exacerbation in the past year. All participants had glycated hemoglobin 
level and inflammatory marker Interleukin-6 (IL-6) concentration assessment, and 
patients with no prior diagnosis of dysglycemia underwent oral glucose tolerance test 
(OGTT).
Results:
76 patients (40.9%) had history of admission for COPD exacerbation, 27 (35.5%) 
of them were known diabetics. Among the remaining 110 patients with stable COPD, 
29 (26.4%) were known diabetics. Mean age was 67.85±9.08 years, mean body mass 
index (BMI) 25.17±6.08 kg/m2, and majority were male (95.2%). Baseline HbAlc in 
the exacerbation group was higher at 6.51±1.48 % compared to 6.22±1.01 % in the 
stable group (p=0.135). Among patients subjected to OGTT (n=130), mean fasting 
blood glucose was 5.43±1.05 mmol/1 with no difference between groups. 2-hour post 
prandial (PP) level was higher in the exacerbation group at 7.91±3.79 mmol/1 
compared to 7.35±2.82 mmol/1 in the stable group (p=0.333). The incidence of new 
dysglycemia were 40.8% (n=20) and 34.6% (n=28) respectively (p=0.574). 
Cumulative days of admission > 6 days/year (OR 4.76, Cl 1.47-15.45) and weight
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CHAPTER ONE 
INTRODUCTION
1.1 RESEARCH BACKGROUND
Chronic obstructive pulmonary disease (COPD) is a group of chronic 
inflammatory pulmonary disorders characterized by progressive partially reversible 
airflow obstruction and airways inflammation (Decramer & Janssens, 2013). Its main 
cause is tobacco smoking, although other factors have been identified as well including 
exposure to air pollution and ageing. Its comorbids, or concomitant chronic diseases, 
include diabetes, cardiovascular disease, osteoporosis and lung cancer.
Acute exacerbation of COPD is defined as sudden worsening of a patient’s 
condition from a stable state into a state that necessitates a change in medication or 
hospitalization (I. D. Pavord, P. W. Jones, P.-R. Burgel, & K. F. Rabe, 2016). It has 
cumulative detrimental effect on lung function, which affects patient’s exercise capacity 
and overall health status and carries significant rate of morbidity and mortality.
According to the World Health Organization (WHO), COPD is set to be the 
third leading cause of death worldwide by 2030 (WHO, 2013). Its burden to the 
healthcare has also been on the rise, owing to the cost of treatment and prolonged 
hospitalizations.
Dysglycemia, a broad term referring to abnormalities in blood glucose level, 
usually refers to diabetes mellitus and pre-diabetes conditions - impaired fasting glucose 
and impaired glucose tolerance. It is known to be one of the major comorbidities of 
COPD, with several previous studies shown an established association between the two 
(Lee, Mao, Lin, Lin, & Hsieh, 2013; Yamane et al., 2013).
While acute exacerbations have been accepted as part of the natural course of 
COPD, it is still arguable if the nature of exacerbation, namely the severity, frequency 
and its treatment, played a role in development of dysglycemia, and patients’ overall 
glycemic control.
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